# A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors

> **NCT05165849** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Zhejiang Genfleet Therapeutics Co., Ltd.**

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** GFS101A
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT05165849
- **Lead sponsor:** Zhejiang Genfleet Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04
- **Primary completion:** 2022-05-11
- **Final completion:** 2022-05-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** sponsor decided to withdraw the study
- **Last updated:** 2022-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05165849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05165849, "A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05165849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*